Stem Cell Treatment for Ulcerative Colitis and Crohn's Disease Patients

experience of ulcerative colitis and crohn n.w
1 / 20
Embed
Share

"Explore the efficacy of fetal stem cell therapy in managing ulcerative colitis and Crohn's disease. Learn about remission criteria, clinical findings, and outcomes for patients with inflammatory bowel diseases. Discover the impact on quality of life and the potential of this innovative treatment approach."

  • Stem Cell Therapy
  • Inflammatory Bowel Disease
  • UC Treatment
  • CD Treatment
  • Fetal Stem Cells
rayaanacharya
mald Follow

Uploaded on | 1 Views

Download Presentation

Please find below an Image/Link to download the presentation.

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.

You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.

Download Presentation

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.

E N D

Presentation Transcript

  1. Experience of Ulcerative Colitis and Crohn s Disease Patients Treatment with Fetal Stem Cell Suspensions

  2. 25 patients with non-specific ulcerative colitis (UC) and 15 patients with Crohn s disease (CD) underwent treatment with fetal stem cells (FSC). Control group consisted of 19 UC and 11 CD patients. FSC transplantation (FSCT) proved to be effective in both acute and chronic non-specific inflammatory bowel diseases, and at all stages, including advanced.

  3. FSCT efficacy was evaluated by: ) Clinical Findings: Remission % N of patients in remission/total N of patients ratio; Time until remission average time span before remission; Term of remission; Life quality improvement subsidence of the following symptoms: stool frequency and consistency, stool admixtures, fever, abdominal pain intensity. ) Blood count: RBC, Hb.

  4. Remission Criteria: UC: Stool frequency 3/day; Absence of blood, mucus in the stool; Absence of abdominal pain, tenesmus, fever, and other systemic problems; No contact hemorrhages, exudates, mucus sponginess and ulceration during rectoromanoscopy. CD: CDAI < 150 (CDAI includes 8 criteria: stool quality, abdominal pain, general well-being, symptoms of external damage of the bowel, antidiarrheal medications intake, abdominal infiltration, hematocrit, body mass)

  5. Reference Group 6 2 11 6 15 10 3 5 Control Group UC Patients Clinical Data % 24 8 44 24 60 40 12 20 5 3 6 5 17 2 1 2 % 26 16 32 26 89 11 5 11 Disease History < 6 months < 1 year 1 5 years > 5 years Moderate Severe Acute Continuous chronic Severity Course Relapsing chronic 17 68 16 84 Damage Degree Left-sided Subtotal Total Moderate High Negative Positive 5 1 19 14 11 19 6 20 4 76 56 44 76 24 8 1 10 17 2 15 4 42 5 53 89 11 79 21 Activity Surgical History Total 25 100 19 100

  6. Reference Group 1 6 5 2 1 - 1 - 9 Conrol Group CD Patients Clinical Data % 6 40 33 13 7 - 7 - 60 2 2 2 2 3 1 2 2 2 % 18 18 18 18 27 9 18 18 18 Disease History < 6 months < 1 year 1 5 years 6 10 years > 10 years Caecum Left-sided Subtotal Total (large bowel) Localization Anastomosis area Prestomal area Rectum stump Anal canal, perianal area - 1 3 1 - 7 20 7 1 - - - 9 - - - Rectum Moderate Severe Negative Positive - 8 7 7 8 15 - 53 47 47 53 100 3 8 3 5 6 11 27 73 27 45 55 100 Severity Surgical History Total

  7. Each UC patient underwent 1 - 8 transplantations, mean 2,29 0,08. Each CD patient underwent 1 - 3 FSCT, mean 1,93 0,06.

  8. Comparative Analysis of the Main Clinical Data of the Reference and Control Groups (UC) R reference group C control group Remission: R - 78,26 6,57%* C - 57,89 8,04 % Need for surgery within 1 months after FSCT: R - 12 6,49% Average time until remission: R - 21 1,06 days C - 26 1,84 days Remission term: R - 14,3 1,84* months C - 9,45 1,27 months C - 21,05 9,35% * - R-C differences are statistically valid, <0,05

  9. Comparative Analysis of the Main Clinical Data of the Reference and Control Groups (CD) R reference group C control group Remission cases: R - 66,67 13,61% R 100% within 7 weeks Average time until remission: R - 4 weeks Remission term: R - 28,3 2,67* months C - 12,5 1,26 months C - 62,5 17,12 % C - 6 weeks * - R-C differences are statistically valid, <0,05

  10. UC Patients Life Quality 120% 96% 96% 96% 100% 89% 76% 80% 55% 60% 44% 40% 40% 27% 17% 20% 12% 11% 5% 0% 0% Diarrhea (doughy stool) Blood Mucus Pus Tenesmus Abdominal pain Fever Before FSCT After 1 month

  11. CD Patients Life Quality 120% 100% 100% 92% 83% 75% 80% 62% 60% 50% 50% 42% 38% 38% 38% 40% 33% 25% 25% 25% 20% 13% 13% 8% 0% 0% 0% Diarrhea (soft stool) Blood Mucus Pus Tenesmus Abdominal Fever Fatigue Joint pain Well-formd pain stool Before FSCT After 1 month

  12. Post-FSCT Defecation Frequency in UC (1 month) 10 9 8 Stool frequency 7 6 5 4 3 2 1 0 Day Ref.Gr. Cont.Gr. p<0,05 in comparison with Cont.Gr.

  13. CDAI Dynamics in CD Patients 450 400 350 300 CDAI points. 250 200 150 100 50 0 0 Week 2 Week 4 Week 6 Week 8 Ref. Gr. Cont.Gr.

  14. Pre- and Post-FSCT RBC Count in UC Reference and Control Groups ( 10^12/l) 4.5 4.3 4.1 3.9 3.7 3.5 3.3 3.1 2.9 2.7 2.5 Before 1 - 3 4 - 7 8 - 14 15 - 29 Days after FSCT 30 - 59 60 - 89 90 - 119 120 - 179 180 - 360 Ref. Gr Cont. Gr

  15. Pre- and Post-FSCT Hb Level in UC Reference and Control Groups (g/l) 140 130 120 110 100 90 80 70 Before 1 - 3 4 - 7 8 - 14 15 - 29 30 - 59 60 - 89 90 - 119 120 - 179180 - 360 Days after FSCT Ref. Gr. Cont. Gr.

  16. Pre- and Post-FSCT RBC Count in CD Reference and Control Groups ( 10^12/l) 4 3.8 3.6 3.4 3.2 3 2.8 2.6 2.4 2.2 2 Before 1-7 8 - 14 15 - 29 30 - 59 60 - 89 120 - 179 180 - 360 Days after FSCT Ref. Gr. Cont. Gr.

  17. Pre- and Post-FSCT Hb Level in CD Reference and Control Groups (g/l) 140 130 120 110 100 90 80 70 60 50 Before 1-7 8 - 14 15 - 29 30 - 59 60 - 89 120 - 179 180 - 360 Days after FSCT Ref.Gr. Cont. Gr. P<0.05 in comparison with the Contr.Gr.

  18. Indications for FSCT in UC and CD Progressive disease, non-responsive to routine therapy after 2 weeks; Extraintestinal complications; Impossibility of surgery due to grave condition caused by anemia, hypoproteinemia, advanced metabolic disorders; Cachexy; Difficulties in finding compatible blood type for transfusion, or donor blood-recipient incompatibility confirmed by the test.

  19. FSCT Contraindications Vasculitis exacerbation: capillaritis, phlebitis, arteritis FSCT is possible after remission, but no earlier than after 3 months; Acute thrombosis: FSCT is possible no earlier than after 3-6 months; Acute ophthalmic hemorrhages: FSCT is possible no earlier than after 3 months; Advanced pulmonary hypertension secondary to vasculitis, thrombosis, pneumonia, accompanied by development of acute or subacute pulmonary heart ; Terminal stage of the disease (expressed intoxication, advanced metabolic dysfunctions and decompensation of internal organs).

  20. Results of FSC Suspensions Application in Combined UC and CD Treatment Inflammation subsidence Shorter time remission Life quality improvement Possibility to postpone or avoid surgery Possibility to reduce the dose of glucocorticoids or discontinue them remission Quick and effective RBC count restoration Co-morbidity prevention until remission and longer without interrupting

Related


No related presentations.

More Related Content